Javascript must be enabled to continue!
Protection from Outpatient Sudden Cardiac Death following ICD Removal Using a Wearable Cardioverter Defibrillator
View through CrossRef
BackgroundAn implantable cardioverter defibrillator (ICD) is effective in preventing sudden cardiac death (SCD). Once an ICD is removed and reimplantation is not feasible, a wearable cardioverter defibrillator (WCD) may be an alternative option. We determined the effectiveness of WCD for SCD prevention in patients who were discharged after ICD removal.MethodsA retrospective study was conducted on all WCD (LifeVest, ZOLL, Pittsburgh, PA, USA) patients who underwent ICD removal due to cardiac device infections (CDIs) at two referral centers between January 1, 2005 and December 31, 2009. Clinical characteristics, device information, and WCD data were analyzed. Sudden cardiac arrest was defined as all sustained ventricular tachycardia (VT) and ventricular fibrillation occurring within a single 24‐hour period.ResultsNinety‐seven patients (mean age 62.8 ± 13.3, male 80.4%) were included in the study. The median duration of antibiotic use was 14.7 days (interquartile range [IQR] 10–30). The median daily WCD use was 20 hours/day and the median length of use was 21 days (IQR 5–47). A total of three patients were shocked by WCD. Two patients had four episodes of sustained VT, successfully terminated by the WCD. A third patient experienced two inappropriate treatments due to oversensitivity of the signal artifact. Three patients experienced sudden death outside the hospital while not wearing the device. Five patients died while hospitalized.ConclusionWCD can prevent SCD, until ICD reimplantation is feasible in patients who underwent device removals for CDI. However, patient compliance is essential for the effective use of this device.
Title: Protection from Outpatient Sudden Cardiac Death following ICD Removal Using a Wearable Cardioverter Defibrillator
Description:
BackgroundAn implantable cardioverter defibrillator (ICD) is effective in preventing sudden cardiac death (SCD).
Once an ICD is removed and reimplantation is not feasible, a wearable cardioverter defibrillator (WCD) may be an alternative option.
We determined the effectiveness of WCD for SCD prevention in patients who were discharged after ICD removal.
MethodsA retrospective study was conducted on all WCD (LifeVest, ZOLL, Pittsburgh, PA, USA) patients who underwent ICD removal due to cardiac device infections (CDIs) at two referral centers between January 1, 2005 and December 31, 2009.
Clinical characteristics, device information, and WCD data were analyzed.
Sudden cardiac arrest was defined as all sustained ventricular tachycardia (VT) and ventricular fibrillation occurring within a single 24‐hour period.
ResultsNinety‐seven patients (mean age 62.
8 ± 13.
3, male 80.
4%) were included in the study.
The median duration of antibiotic use was 14.
7 days (interquartile range [IQR] 10–30).
The median daily WCD use was 20 hours/day and the median length of use was 21 days (IQR 5–47).
A total of three patients were shocked by WCD.
Two patients had four episodes of sustained VT, successfully terminated by the WCD.
A third patient experienced two inappropriate treatments due to oversensitivity of the signal artifact.
Three patients experienced sudden death outside the hospital while not wearing the device.
Five patients died while hospitalized.
ConclusionWCD can prevent SCD, until ICD reimplantation is feasible in patients who underwent device removals for CDI.
However, patient compliance is essential for the effective use of this device.
Related Results
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: data from Monaldi Rhythm Registry
Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: data from Monaldi Rhythm Registry
IntroductionSubcutaneous ICD (S-ICD) is an alternative to a transvenous implantable cardioverter-defibrillator (TV-ICD) system in selected patients not in need of pacing or resynch...
The effects of age on quality of life in implantable cardioverter defibrillator recipients
The effects of age on quality of life in implantable cardioverter defibrillator recipients
Background. The implantable cardioverter defibrillator shows superiority over conventional pharmacological therapy. The implantable cardioverter defibrillator has been implanted w...
Benefit of Implantable Cardioverter Defibrillator Use in Japanese Patients Based on Modified MADIT-ICD Benefit Score
Benefit of Implantable Cardioverter Defibrillator Use in Japanese Patients Based on Modified MADIT-ICD Benefit Score
Abstract
Aims
The MADIT-ICD benefit score is used to stratify the risk of life-threatening arrhythmia and non-arrhythmic ...
Arrythmic storm in patients with and without an implantable cardioverter defibrillator
Arrythmic storm in patients with and without an implantable cardioverter defibrillator
Abstract
Introduction
Available data on arrhythmic storm (AS) is frequently obtained from retrospective observational series of ...
The Clinical and Economic Impact of Extended Battery Longevity of a Substernal Extravascular Implantable Cardioverter Defibrillator
The Clinical and Economic Impact of Extended Battery Longevity of a Substernal Extravascular Implantable Cardioverter Defibrillator
Background and Aims:
The extravascular implantable cardioverter
defibrillator (EV ICD) has an extended projected battery longevity
compared to the subcutaneous im...
Clinical outcomes of subcutaneous vs. transvenous implantable defibrillator therapy in a polymorbid patient cohort
Clinical outcomes of subcutaneous vs. transvenous implantable defibrillator therapy in a polymorbid patient cohort
BackgroundThe subcutaneous implantable cardioverter-defibrillator (S-ICD) has been designed to overcome lead-related complications and device endocarditis. Lacking the ability for ...
Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial
Impact of Cardiac Resynchronization Therapy on Hospitalizations in the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial
Background—
This study reports the impact of cardiac resynchronization therapy (CRT) on hospitalizations in patients randomized to implantable cardioverter-defi...

